Home GlaxoSmithKline targets growth across units, scraps ViiV listing
 

Keywords :   


GlaxoSmithKline targets growth across units, scraps ViiV listing

2015-05-06 15:04:09| Biotech - Topix.net

It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook, and promised to pay a steady dividend of 80 pence a share over the next three years. Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion-plus asset swap with Novartis can revive GSK's fortunes, following a damaging slide in lung drug sales and a major corruption scandal in China.

Tags: listing growth units targets

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11STEINBACH40
24.11 Sepua Crue F-170
24.11 SECRET
24.11CRAwith
24.1111/15)&&
24.11 8
24.11
24.11F2023 23
More »